Patients arriving for aesthetic consultations and weight management visits are increasingly asking about NAD+. They’ve heard about it from longevity podcasts, seen it on the menu at concierge clinics, or read about it in the same places they learned about GLP-1s.
Providers who can give a calibrated, clinical answer — and offer it appropriately — are capturing a patient segment that sits at the intersection of three growing revenue streams: aesthetics, weight management, and longevity medicine. Those who can’t are losing that conversation to the wellness clinic down the street.
What you will learn in this article:
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, essential to hundreds of metabolic reactions, including cellular energy production, DNA repair, and the regulation of cellular senescence, the process by which aging cells stop dividing but remain metabolically active in ways that accelerate tissue aging.
Research at the intersection of regenerative medicine and cosmetic dermatology confirms that NAD+ levels decline measurably with age, and that this decline is linked to inflammaging — the chronic low-grade inflammatory state that accelerates tissue aging — as well as reduced cellular resilience, metabolic slowdown, and the kinds of skin aging changes aesthetic patients are presenting with. For practices already serving GLP-1 weight loss patients who arrive with both metabolic and cellular aging concerns, NAD+ fits a clinical framework that’s already in place.
Oral NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — are widely available and actively marketed. The clinical limitation is pharmacokinetic: first-pass metabolism in the liver processes most oral NAD+ precursors before they reach peripheral tissues like skin and muscle, which are the tissues most relevant to aesthetic and metabolic outcomes. IV delivery bypasses this entirely.
A pilot pharmacokinetics study found that plasma NAD+ levels don’t begin rising until approximately 2 hours into IV infusion, meaning the body processes IV NAD+ through distinct pathways, and sessions under 2 hours may fail to deliver meaningful tissue levels.
That’s not a minor operational note: it determines how sessions should be structured, how they should be priced, and how providers should differentiate their offering from the supplement aisle.
The mechanism behind NAD+ is scientifically well-grounded. Early-phase human trials are underway across longevity and metabolic applications, and the evidence base for NAD+’s role in cellular senescence and DNA repair pathways is established.
Skin-specific clinical efficacy data for aesthetic indications is still preliminary — this is frontier territory where the mechanistic rationale is stronger than the completed RCT evidence.
Providers who frame it as a longevity intervention with sound mechanistic support and emerging clinical data are on defensible ground. Those claiming it reverses skin aging or guarantees specific aesthetic outcomes are ahead of what the evidence supports. The honest position, that the science is compelling and the clinical data is developing, is also the one that builds long-term patient trust.
The target market for IV NAD+ is largely already in the practice. GLP-1 weight loss patients interested in metabolic optimization and cellular health are a natural fit, as are aesthetic patients asking about skin quality from the inside out and anyone already engaged with longevity medicine through concierge clinics, functional wellness, or their own research.
These patients are motivated and informed as they’ve often already looked into NAD+ before the appointment. The question is whether they’re finding it at your practice or somewhere else. Practices offering both weight management and aesthetic services have a structural advantage here: the whole-patient framing is already built in.
Based on the pharmacokinetics, session duration should be 2–4 hours — shorter infusions may not deliver plasma levels that translate to meaningful tissue availability.
Dosing ranges typically from 250mg to 1,000mg per session, with most aesthetic and wellness applications falling in the 250mg–500mg range.
Pricing reflects both the clinical time and the premium nature of the service: standard 250mg sessions typically run $300–$500, with 1,000mg protocols reaching $800–$1,500+ in most markets.
An emerging model worth considering: membership or subscription pricing — monthly programs in the $169+ range are gaining traction in aesthetic clinics as a way to convert one-time NAD+ patients into recurring revenue. Unlike high-volume injectable services, IV NAD+ is a high-margin, high-engagement offering — patients are in the chair for 2–4 hours, creating the kind of extended provider interaction that builds retention.
Infrastructure requirements are manageable for most practices already offering any form of IV therapy. The essentials: IV poles and appropriate delivery equipment, comfortable reclined seating for multi-hour sessions, staff trained in IV administration, a clinical monitoring protocol, and patient consent and documentation processes appropriate to the service.
For practices not yet offering any IV services, the staffing and training investment is the primary consideration — not equipment or space.
NAD+ is a useful indicator of a broader shift. The patient who books for Botox now may also be on a GLP-1, tracking their biological age, and asking what else the practice can do for energy, cognition, and cellular health.
The separation between “looking good,” “feeling good,” and “aging well” is collapsing in the patient’s mind, and the practices that can serve that whole picture are building a different kind of practice than those that stay lane-specific.
IV NAD+ is one piece of that convergence. For a broader look at where longevity medicine is entering aesthetic practice, the IAPAM Medical Weight Management Library and How to Start a Weight Loss Clinic hub cover the infrastructure side of building this kind of practice.
Providers looking to add IV NAD+ within a structured, certified framework have a clear path. The Certified Medical Weight Management Provider Program includes IV therapy content and is the structured on-ramp for practices that want to add IV NAD+ services alongside weight management. For providers looking to extend their aesthetic practice into regenerative medicine, the Certified Aesthetic Provider Program covers PRP and the core aesthetic foundations — and a dedicated stem cell course is being added to the curriculum soon for providers ready to go deeper into regenerative techniques. The practices positioned to win with longevity-minded patients are building competency on both sides.
What is NAD+ and why is it relevant to aesthetic medicine?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential to cellular energy production, DNA repair, and the regulation of cellular senescence — the aging process at the cellular level. NAD+ levels decline with age, and that decline is linked to the tissue aging changes aesthetic patients present with: reduced skin quality, slower cellular repair, and the metabolic shifts that accompany both natural aging and rapid weight loss. For aesthetic practices, the relevance is both clinical and commercial: it connects what providers already do to a broader longevity conversation patients are already having.
What is the difference between IV NAD+ and oral NAD+ supplements?
The difference is pharmacokinetic. Oral NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are processed by the liver before they can reach peripheral tissues — a limitation called first-pass metabolism. IV delivery bypasses this entirely, introducing NAD+ directly into circulation. Research shows plasma NAD+ levels don’t begin rising until approximately 2 hours into IV infusion, which is why session duration matters and why IV NAD+ represents a clinically distinct intervention, not a more expensive version of a supplement.
How long should an IV NAD+ session be?
Based on pharmacokinetics research, sessions should run 2–4 hours. Plasma NAD+ levels don’t begin to rise meaningfully until approximately 2 hours into infusion, meaning shorter sessions may not deliver tissue levels sufficient to produce the intended effect. This has direct implications for practice logistics and pricing: IV NAD+ is not a quick-drip service. The extended session time is also an opportunity — patients in the chair for 2–4 hours have extended provider interaction time that can deepen the clinical relationship.
What does IV NAD+ therapy cost, and how should I price it?
Standard 250mg sessions typically run $300–$500 in most US and Canadian markets, with 1,000mg high-dose protocols reaching $800–$1,500+. Pricing varies by market, dose, and whether the session is bundled with complementary IV services. Membership or subscription models — monthly programs in the $169+ range — are emerging as a retention tool in aesthetic clinics offering ongoing NAD+ maintenance. IV NAD+ is best positioned as a high-margin, high-engagement service — not compared to injectable treatments priced per unit. The 2–4 hour session duration and clinical infrastructure required support premium pricing relative to other IV drip services.
Can IV NAD+ therapy be bundled with other services?
Yes, and this is a common practice model. IV NAD+ pairs well with complementary IV therapies — glutathione, vitamin C, hydration, Myers cocktail — and can be incorporated into a broader longevity wellness protocol. For practices already offering GLP-1 weight management, NAD+ fits naturally into a metabolic optimization framework. Bundling increases per-visit revenue and reinforces the whole-patient, longevity-oriented practice positioning that retains this patient type long-term.
Is IV NAD+ therapy FDA approved?
IV NAD+ is administered under provider discretion as part of wellness protocols and does not carry a specific FDA approval for aesthetic or longevity indications. This is consistent with how many IV wellness therapies are offered — the provider’s medical judgment governs the clinical decision to use it. Appropriate patient consent, documentation, and clinical oversight are required, as with any IV service. Providers should ensure their practice’s liability coverage includes IV therapy services and that staff training meets applicable state board requirements.
Which patients are the best candidates for IV NAD+ therapy?
Patients with the strongest fit are those already engaged with longevity, metabolic health, or whole-patient wellness: GLP-1 weight loss patients interested in cellular optimization alongside their weight management; aesthetic patients focused on skin quality and anti-aging from a systemic perspective; and any patient who’s already asking about NAD+ or longevity medicine. These patients tend to be research-oriented, motivated, and interested in a longer-term provider relationship — which makes them well-suited to the multi-visit, high-engagement model that IV NAD+ naturally supports.
Get Your Free GLP-1 Quick Start Action Plan
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
